Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 18/20 | 0.66 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.65 |
| ▸ | CDK1 | P06493 | 2/20 | 0.65 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.65 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.65 |
| ▸ | GSK3A | P49840 | 1/20 | 0.64 |
| ▸ | GSK3B | P49841 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | SNCA | P37840 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24655593 | 0.83 | RIPK1 (0.71) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL14069325 | 0.81 | RIPK1 (0.68) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1778505 | 0.80 | RIPK1 (0.74) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL31064988 | 0.80 | RIPK1 (0.58) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL5907874 | 0.80 | RIPK1 (0.71) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL31065045 | 0.80 | RIPK1 (1.00) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL7892114 | 0.80 | RIPK1 (0.71) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL18741322 | 0.80 | RIPK1 (1.00) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1780494 | 0.80 | RIPK1 (0.71) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL31265224 | 0.80 | RIPK1 (0.71) | RIPK1CCNB2CDK1CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION | 2008-04-03 | — | — | US | disclosed |
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | RIPK1 548/4885CCNB2 106/4885CDK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.